News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Daily News AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD Caitlin E. Cox December 28, 2021
News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2020 Shelley Wood November 30, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020